Sana Biotechnology (SANA) Accumulated Expenses (2020 - 2026)

Sana Biotechnology (SANA) has 7 years of Accumulated Expenses data on file, last reported at $2.8 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 14.43% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (down 14.43% YoY), and the FY2025 full-year result was $8.8 million, down 33.28% from the prior year.
• Accumulated Expenses declined to $2.8 million in Q1 2026, from $8.8 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $21.3 million in Q2 2024 to a low of $2.0 million in Q3 2025.
• A 5-year average of $7.3 million and a median of $5.2 million in 2023 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses slumped 76.08% in 2023 and surged 236.38% in 2024, its largest moves.
• Tracing SANA's Accumulated Expenses over 5 years: stood at $16.5 million in 2022, then tumbled by 76.08% to $3.9 million in 2023, then surged by 236.38% to $13.2 million in 2024, then tumbled by 33.28% to $8.8 million in 2025, then plunged by 68.37% to $2.8 million in 2026.
• Business Quant data shows SANA's Accumulated Expenses at $2.8 million in Q1 2026, $8.8 million in Q4 2025, and $2.0 million in Q3 2025.